566 related articles for article (PubMed ID: 17826043)
41. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
[TBL] [Abstract][Full Text] [Related]
42. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
43. Treating diabetes: cardiovascular benefits of antidiabetes drugs.
Harmel AP
Am J Manag Care; 2002 May; 8(8 Suppl):S219-28; quiz S229-32. PubMed ID: 12022237
[TBL] [Abstract][Full Text] [Related]
44. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
Fonarow GC
Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular effects of the thiazolidinediones.
Qayyum R; Schulman P
Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
[TBL] [Abstract][Full Text] [Related]
46. Primary prevention of cardiovascular disease in people with dysglycemia.
Bianchi C; Miccoli R; Penno G; Del Prato S
Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
[TBL] [Abstract][Full Text] [Related]
47. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors.
Zarich SW
Rev Cardiovasc Med; 2003; 4 Suppl 6():S19-28. PubMed ID: 14668700
[TBL] [Abstract][Full Text] [Related]
48. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
49. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.
Schernthaner G
Int J Clin Pract; 2009 Jun; 63(6):912-29. PubMed ID: 19490202
[TBL] [Abstract][Full Text] [Related]
50. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
51. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
[TBL] [Abstract][Full Text] [Related]
52. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
Tkác I
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
[TBL] [Abstract][Full Text] [Related]
53. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
Rosenberg DE; Jabbour SA; Goldstein BJ
Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
[TBL] [Abstract][Full Text] [Related]
54. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M
Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460
[TBL] [Abstract][Full Text] [Related]
55. Global risk management in patients with type 2 diabetes mellitus.
Davidson MH
Am J Cardiol; 2007 Feb; 99(4A):41B-50B. PubMed ID: 17307057
[TBL] [Abstract][Full Text] [Related]
56. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
57. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
58. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies.
Zoungas S; Patel A
Ann N Y Acad Sci; 2010 Nov; 1212():29-40. PubMed ID: 21091713
[TBL] [Abstract][Full Text] [Related]
59. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
60. Lipid management in patients with diabetes mellitus.
Brown AS
Am J Cardiol; 2005 Aug; 96(4A):26E-32E. PubMed ID: 16098840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]